Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 34

recruiting
3 972
countries
28
conditions
2 103

467 trials match your criteria

Cholangiocarcinoma+1

Not recruiting

Study on the Effectiveness and Safety of Gemcitabine, Cisplatin, Trastuzumab, and Pembrolizumab for Untreated HER2-Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Small cell lung cancer limited stage

Not recruiting

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab, Trastuzumab, and Chemotherapy for Patients with HER2 Positive Advanced Stomach or Gastroesophageal Junction Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Fallopian tube cancer+1

Not recruiting

Study of Pembrolizumab, MK-4830, and Chemotherapy for Patients with High-Grade Serous Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness and Safety of Lenvatinib, Pembrolizumab, and Chemotherapy for Patients with Advanced or Metastatic Gastroesophageal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab

Prostate cancer

Not recruiting

Study of Pembrolizumab and Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide

Thymoma+1

Not recruiting

Study on Pembrolizumab and Lenvatinib for Patients with Pre-Treated Thymic Carcinoma and B3-Thymoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Transitional cell cancer of the renal pelvis and ureter

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.